Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus
Arch. endocrinol. metab. (Online)
;
66(6): 868-870, Nov.-Dec. 2022.
Artigo
em Inglês
|
LILACS-Express
| LILACS
| ID: biblio-1403249
ABSTRACT
"What's in a name? That which we call a rose / By any other name would smell as sweet" (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare's implication is that a name is nothing but a word and it therefore represents a convention with no intrinsic meaning. Whilst this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence, there must be a very good rational for changing the name of a disease that has a centuries-old historical context. A working group of representatives from national and international endocrinology and endocrine pediatric societies now proposes changing the name of "diabetes insipidus" to "Arginine Vasopressin Deficiency (AVP-D)" for central etiologies, and "Arginine Vasopressin Resistance (AVP-R)" for nephrogenic etiologies This editorial provides both the historical context and the rational for this proposed name change.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Idioma:
Inglês
Revista:
Arch. endocrinol. metab. (Online)
Assunto da revista:
Endocrinologia
/
Metabolismo
Ano de publicação:
2022
Tipo de documento:
Artigo
País de afiliação:
Austrália
/
Brasil
/
Japão
/
Suíça
/
Estados Unidos
/
Reino Unido
Instituição/País de afiliação:
Georgetown University/US
/
Nagoya University Graduate School of Medicine/JP
/
Newcastle University/GB
/
Non-executive Director Pituitary Foundation/GB
/
St Vincents Hospital/AU
/
Universidade Federal de Minas Gerais/BR
/
University Hospital and University of Basel/CH
/
University Hospitals of Leicester NHS Trust/GB
/
University of Cambridge & Addenbrookes Hospital/GB
/
University of Oxford/GB
Similares
MEDLINE
...
LILACS
LIS